Protocol Ledger

Academic / Cooperative Group · Consolidated Sponsor Hub

Memorial Sloan Kettering Cancer Center: Clinical Trials & FDA Approval Profile

Memorial Sloan Kettering Cancer Center (New York, NY) sponsors 308 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 236 active protocols (131 recruiting now), 44 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.1%
Median Closed Enrollment vs National (145 pts)24 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Memorial Sloan Kettering Cancer Center
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)308
Active Pipeline (Recruiting Now)236 (131)
Completed vs Stopped Early44 / 28 (9.1%)
Median Closed Actual Enrollment24 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Memorial Sloan Kettering Cancer Center
Hospital Research SiteLocationShared Protocols
Memorial Sloan Kettering Cancer CenterNew York, NY298
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, NJ131
Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, NJ129

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Memorial Sloan Kettering Cancer Center
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05657873A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)Phase IIRECRUITING
NCT07111507A Study of Tarlatamab for People With Prostate CancerPhase IIRECRUITING
NCT05188508Pembrolizumab, Olaparib, and Temozolomide for People With GliomaPhase IIRECRUITING
NCT04165772Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid TumorsPhase IIRECRUITING
NCT06594991A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaPhase IIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Memorial Sloan Kettering Cancer Center Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI